GenEditBio
GenEditBio is a clinical-stage Hong Kong-headquartered biotechnology company developing CRISPR-based in vivo genome-editing therapies for ocular, cardiovascular, and rare genetic diseases, leveraging proprietary LNP and PDV delivery platforms and the AI-integrated GenomePAM nuclease discovery platform.
- Company typePrivate
- Founded2021
- HeadquartersBeijing, China
- Headcount51–100
- GTM typeB2B
- OfferingServices
What GenEditBio does
GenEditBio (GenEditBio Limited) is a clinical-stage biotechnology company founded in 2021 and headquartered in Hong Kong, with research operations in Beijing and a supporting office in Boston. The company develops CRISPR-based in vivo genome-editing therapies — framed as "DNA surgery" — for genetic diseases with unmet medical needs, with primary focus on ocular, metabolic, rare, and cardiovascular indications. Its lead program GEB-101 is a first-in-class, single intrastromal injection CRISPR-Cas therapy for TGFBI corneal dystrophy; it received FDA IND clearance in January 2026 and NMPA clinical trial approval in July 2026, with a Phase 1/2 CLARITY trial underway in the United States. A second program, GEB-200, targets cardiovascular disease and is being advanced through a cross-license with ToolGen.
The company's underlying technology platform integrates three pillars: (1) GenomePAM, an AI-integrated system for PAM characterization and engineering of CRISPR-Cas nucleases using mammalian genome repeats and AlphaFold 3, published in Nature Biomedical Engineering; (2) Protein Delivery Vehicles (PDV), replication-incompetent viral-like particles for in vivo RNP delivery with programmable tissue targeting; and (3) Lipid Nanoparticle (LNP) delivery technology with proprietary NHP-barcoded high-throughput screening. Novel high-fidelity Cas nucleases (SpCas9-HF, SaCas9-HF) and off-target monitoring methods (GUIDE-Seq, EDITED-Seq) underpin the editing precision layer.
GenEditBio is pre-commercial and does not yet generate product revenue. Its forward revenue mechanics are structured around two streams: future therapeutic development and commercialization of its pipeline (potentially via licensing or direct sales through clinical trial sites and ultimately healthcare providers), and technology licensing and partnerships generating upfronts, milestones, and royalties — exemplified by the ToolGen cross-license and the Yimingbio/Ubrigene LNP ex vivo licensing deal. The company sells through enterprise field sales motions targeting pharmaceutical partners, CROs, and global investigators, and reaches investors and partners through international biotech conferences such as the BioCentury-BayHelix East-West Summit and Web Summit Qatar. Backed by $90 million in disclosed financing (April 2024) led by Center Ventures and Shuntian Pharmaceuticals, plus Qiming Venture Partners, HKSTP, and others, and recognized on the Forbes Asia 100 To Watch 2025 list, GenEditBio operates with 51–100 employees across Hong Kong, Beijing, and Boston.
GenEditBio firmographics
Firmographics- Name
- GenEditBio
- Legal name
- GenEditBio Limited
- Website
- https://geneditbio.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- GenEditBio is a clinical-stage Hong Kong-headquartered biotechnology company developing CRISPR-based in vivo genome-editing therapies for ocular, cardiovascular, and rare genetic diseases, leveraging proprietary LNP and PDV delivery platforms and the AI-integrated GenomePAM nuclease discovery platform.
- Ownership category
- akta.pro rank
GenEditBio industry classification
Industry- Product category
- Gene Therapy
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Genome Editing Gene Therapies (CRISPR/TALEN/ZFN; in vivo/ex vivo) (HLAAACAD)
- akta.pro secondary industries
- Gene Therapy for Rare/Monogenic Diseases (HLAAACAE), Cardiometabolic & Other Systemic Gene Therapies (HLAAACAI), Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery) (HLAAACAL), CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq) (HLAAAIAG)
Keywords
Where GenEditBio is headquartered
LocationHeadquarters
- HQ city
- Beijing
- HQ country
- China
- HQ region
- Asia
Offices3 records
Markets served
GenEditBio business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
Revenue model
- Therapeutic Development and Commercialization: GenEditBio is a clinical-stage biotechnology company developing CRISPR-based genome editing therapies. The company generates revenue through the development and potential commercialization of its therapeutic pipeline, including GEB-101 for TGFBI corneal dystrophy and GEB-200 for cardiovascular disease.
- Technology Licensing and Partnerships: The company engages in strategic licensing agreements and partnerships, such as the cross-license agreement with ToolGen, to develop and commercialize genome-editing therapeutics, generating revenue through upfront payments, milestone payments, and royalties.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels3 records
GenEditBio product offering
Product offeringCore offering
GenEditBio is a clinical-stage biotechnology company developing CRISPR-Cas based in vivo genome editing therapies for genetic diseases. Its integrated platform combines proprietary lipid nanoparticle (LNP) and protein delivery vehicle (PDV) delivery technologies, novel Cas nucleases, and the GenomePAM AI platform for nuclease discovery. The lead clinical asset GEB-101 is a first-in-class CRISPR therapy for TGFBI corneal dystrophy, with GEB-200 in development for cardiovascular disease.
Product overview
GenEditBio is a clinical-stage biotechnology company developing CRISPR-based precision genome editing medicines. The company's integrated platform combines three core technologies: LNP (Lipid Nanoparticle) delivery technology for organ/tissue targeting, PDV (Protein Delivery Vehicle) for viral-like in vivo RNP delivery, and GenomePAM for AI-powered CRISPR-Cas nuclease discovery and engineering. The lead clinical program GEB-101 is a first-in-class CRISPR therapy for TGFBI corneal dystrophy, with GEB-200 in development for cardiovascular disease. The company focuses on 'one-and-done' in vivo gene editing therapies targeting ocular, metabolic, and rare diseases.
Differentiator
Problem solved
Functional benefit
Products and services
- GEB-101 First-in-class CRISPR-Cas based in vivo genome editing therapy for TGFBI corneal dystrophy, delivered via single intrastromal injection using ribonucleoprotein (RNP) formulation. Targeting patients with TGFBI corneal dystrophy.
- GEB-200 In vivo genome editing therapeutic candidate for cardiovascular disease, developed in collaboration with ToolGen using CRISPR-Cas9 platform and GenEditBio's lipid nanoparticle delivery technology. Targets cardiovascular genetic conditions with unmet needs.
- GenomePAM Platform AI-integrated scalable platform for protospacer adjacent motif (PAM) characterization and engineering of CRISPR-Cas nucleases using mammalian genome repeats. Achieves at least 10-bit width PAM analysis compared to traditional 5-6 bit width methods, accelerating novel Cas nuclease discovery.
- Protein Delivery Vehicle (PDV) Proprietary replication-incompetent viral-like particle for in vivo delivery of genome editors as RNP, featuring programmable tissue targeting via surface glycoproteins and molecules, high cargo compatibility and large cargo capacity.
- Lipid Nanoparticle (LNP) Delivery Technology Proprietary lipid nanoparticle delivery platform featuring barcoding technology that enables high-throughput screening directly on nonhuman primates, with diverse lipid components enabling organ/tissue targeting without requiring antibody conjugation.
Quantifiable outcome
- FDA IND clearance achieved for GEB-101, marking transition from preclinical to clinical stage
- +2 more outcomes
Companies that use GenEditBio
Customer profileSegments1 record
Ideal customer profiles3 records
GenEditBio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature4 records
GenEditBio partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- 宜明生物 (Yimingbio/Ubrigene)coreStrategic collaboration to develop next-generation LNP ex vivo delivery technology. Yimingbio licensed GenEditBio's LNP technology for ex vivo applications and will leverage its global CRDMO production services for engineering integration and product development. Focus on developing efficient, low-toxicity RNA-LNP ex vivo delivery standardized ready-to-use reagent products for cell and gene therapy.
- ToolGen Inc.coreStrategic cross-license agreement for the development of in vivo genome-editing therapeutics. Collaboration leverages ToolGen's CRISPR-Cas9 platform and GenEditBio's lipid nanoparticle delivery technology. Focuses on 'once-and-done' treatment for diseases with unmet needs, with promising preclinical results on GEB-200 for cardiovascular disease.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
GenEditBio competitors and assessment
Company assessmentDirect peers
- CRISPR Therapeutics: Pioneering CRISPR/Cas9-based gene editing company with approved therapy (Casgevy) and broad pipeline. Direct peer with overlapping gene editing platform and delivery technology approaches for in vivo applications.
- Beam Therapeutics: Clinical-stage precision genetic medicines company developing base editing therapies for serious diseases. Comparable gene editing platform with similar in vivo delivery challenges and clinical development profile to GenEditBio.
- Caribou Biosciences: Clinical-stage CRISPR gene editing company with allogeneic CAR-T and other cell therapy programs. Comparable gene editing platform development with similar clinical-stage status and strategic focus on genetic disease treatment.
- Prime Medicine: Clinical-stage biotechnology company developing prime editing therapies for genetic diseases. Direct peer in next-generation gene editing platform development with similar clinical-stage profile and therapeutic focus.
- Editas Medicine: Clinical-stage CRISPR gene editing company developing in vivo and ex vivo therapies for serious diseases, including ocular programs. Direct competitor to GenEditBio in CRISPR-based genome editing medicines targeting similar indications.
- Verve Therapeutics: In vivo gene editing company focused on cardiovascular disease, with clinical-stage programs using LNP delivery of base editors. Highly comparable to GenEditBio's GEB-200 program in cardiovascular indications and LNP delivery approach.
- Intellia Therapeutics: Leading in vivo CRISPR/Cas9 gene editing company with clinical-stage programs across multiple therapeutic areas including cardiovascular and rare diseases. Closely comparable technology platform and business model to GenEditBio.
- ToolGen Inc. CRISPR-Cas9 platform company and GenEditBio's strategic partner through cross-license agreement. Develops genome editing therapeutics with comparable technology stack, though primarily focused on research tools and platform licensing.
Emerging players
- Acuitas Therapeutics: LNP delivery technology company supporting multiple gene therapy developers including COVID-19 vaccines. Comparable LNP delivery platform expertise, though operates primarily as enabling technology provider rather than therapy developer.
- Scribe Therapeutics: Emerging CRISPR-based gene editing company developing engineered Cas nucleases for therapeutic applications. Emerging player with comparable novel nuclease discovery focus similar to GenEditBio's GenomePAM platform.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
GenEditBio social profiles
Digital presenceGenEditBio financial estimates
Financial estimateRevenue estimate
Valuation estimate
GenEditBio leadership team
Management profileNumber of profiles
Profiles2 records
GenEditBio funding detail
Funding detailFunding overview
Funding rounds3 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
GenEditBio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about GenEditBio
What does GenEditBio do?
GenEditBio is a clinical-stage biotechnology company developing CRISPR-Cas based in vivo genome editing therapies for genetic diseases. Its integrated platform combines proprietary lipid nanoparticle (LNP) and protein delivery vehicle (PDV) delivery technologies, novel Cas nucleases, and the GenomePAM AI platform for nuclease discovery. The lead clinical asset GEB-101 is a first-in-class CRISPR therapy for TGFBI corneal dystrophy, with GEB-200 in development for cardiovascular disease.
Is GenEditBio a public or private company?
GenEditBio is a private company. It is classified as venture growth investor backed and is currently operating.
When was GenEditBio founded?
GenEditBio was founded in 2021. It employs 51 to 100 people.
Where is GenEditBio based?
GenEditBio is headquartered in Beijing, China, in the Asia region.
How does GenEditBio make money?
Two revenue lines are on record. Therapeutic Development and Commercialization is the primary driver. The others are technology Licensing and Partnerships.
Who are GenEditBio's main competitors?
Direct peers on record are CRISPR Therapeutics, Beam Therapeutics, Caribou Biosciences, Prime Medicine, Editas Medicine, Verve Therapeutics, Intellia Therapeutics and ToolGen Inc.. Emerging players are Acuitas Therapeutics and Scribe Therapeutics.
Does GenEditBio have an API?
No public API is recorded for GenEditBio.
What industry is GenEditBio in?
GenEditBio's product category is Gene Therapy. Its primary akta.pro industry code is HLAAACAD, Genome Editing Gene Therapies (CRISPR/TALEN/ZFN; in vivo/ex vivo), with a secondary code of HLAAACAE, Gene Therapy for Rare/Monogenic Diseases. Its NAICS code is 541714 and its SIC code is 8731.